Clinical Trials
Multiple clinical trials evaluate the metabolic and physiological effects of Lac-Phe and related supplementation strategies in cohorts with obesity as well as healthy overweight individuals. Sponsored by academic and commercial institutions including the University of Aarhus, Aarhus University Hospital, and Novo Nordisk A/S, these unphased studies feature statuses ranging from active recruitment to completed. Ultimately, these investigations aim to characterize the physiological impact of this exercise-induced signaling metabolite in humans.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06743009 | COMPLETED | Healthy Overweight/Obese |
University of Aarhus |
2025-05-13 | |
| NCT05917873 | Recruiting | Obesity |
University of Aarhus|Novo Nordisk A/S|Aarhus University Hospital|Riisfort |
2023-09-07 | Not Applicable |
(data from https://clinicaltrials.gov, updated on 2026-03-27)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).